Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747006 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake
A Phase 2 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00747006 is a Phase 2 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 18 participants.
The verdict
NCT00747006, a Phase 2 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if, once a favorable dose of TI Inhalation Powder is established for either a type 1 or 2 patient, based on a average diabetic meal, the patient's favorable dose can be used safely, regardless of change in meal carbohydrate content. Patients were randomly assigned to various carbohydrate loads (0%, 50%, 100%, 150% or 200%). The 100% carbohydrate load was determined based upon their standard insulin dose for their normal meal.
Interventions
- DRUG TI Inhalation Powder and Humalog (Amendment 1)
- DRUG TI Inhalation Powder (original protocol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747006
The ClinicalTrials.gov registry entry for NCT00747006 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TI Inhalation Powder and Humalog (Amendment 1) is the first listed.
NCT00747006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00747006 about?
NCT00747006 is a clinical study titled "Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake". The purpose of this study is to determine if, once a favorable dose of TI Inhalation Powder is established for either a type 1 or 2 patient, based on a average diabetic meal, the patient's favorable dose can be used safely, regardless of change in meal carbohydrate content. Patients were randomly as...
What is the current status of trial NCT00747006?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00747006?
The interventions under investigation include: TI Inhalation Powder and Humalog (Amendment 1) (DRUG), TI Inhalation Powder (original protocol) (DRUG).
Who is sponsoring clinical trial NCT00747006?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.